Study Group: Maraviroc Experts (?)
Council Members in this Study Group: 42
Request a survey with this Study Group
Leading Experts in this Study Group
Physician
University Of Rochester Medical Center
Steven Fine, MD, PhD, is an HIV and Infectious Disease specialist, an Assistant Professor in the Infectious Disease Unit at the University of Rochester Medical Center, and Staff Physician at Community Health Network. His clinical expertise is all aspects of HIV/AIDS care. Dr. Fine has published research...
Associate Clinical Professor of Medicine
University of California, San Francisco
George Beatty, MD, MPH, is an Associate Clinical Professor of Medicine at the University of California San Francisco, since July 2008. He served as Director of the UCSF's HIV Clinical Trials in the Positive Health Program at San Francisco General Hospital from 2001 to 2007. Dr. Beatty has 13 years of...
Assistant Clinical Professor of Medicine
New York- Presbyterian/Columbia University Medical Center
Jin Suh, MD, is an Assistant Clinical Professor of Medicine at the Columbia University College of Physicians and Surgeons. He is also an Associate Medical Director of the HIV-AIDS Program at St. Luke's-Roosevelt Hospital, New York. Dr. Suh is board certified in Internal Medicine and Infectious Disease....
Related Study Groups
| Study Group Name | Members |
|---|---|
| Infectious Diseases Physicians (US) | 908 |
| HIV Specialists (US) | 369 |
| Fuzeon Prescribers for HIV (US) | 43 |
| Viread Prescribers for HIV (US) | 30 |
| Prescribers of Combivir : HIV Specialists (US) | 35 |
| Cubicin Prescribers (US) | 171 |
| Pathologists (US) | 824 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The HLAB5701 test is inexpensive and uncomplicated to perform It reduces risk of the hypersenitivity reaction. Two recent studies have raised concerns about abacavir. -ACTG 5202 study has indicated that in persons with high viral loads epzicom (the main brand of abacavir)...
After the extensive studies published (Mallal et al), it becomes mandatory to perform a genetic HLA screening before starting abacavir-containing antiretroviral associations. Problems are recognizable in these points: - laboratories are not capable to front an exaggerated request of HLA typing; - ad-hoc...
Impressive 7 day antiviral effects Potential for QD naive and BD experienced approaches Potential for coformulations Revised formulation moving into next phase of testing No critical safety issues in volunteers or patients Metabolit may be anti-gout agent
Etravirine is a novel and very promising NNRTI since it has not cross-resistance with the existing NNRTIs (efavirenz and nevirapine), and also encompasses excellent efficacy, convenience, and a good tolerability.
A new NNRTI that overcomes class resistance and with a low threshold for development of resistance will be a useful addition to our antiretroviral armamentarium.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Government/Military Hospital or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
- Private/For-Profit Healthcare Research Entity
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Medical Director
- Director
- Principal
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms